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ABSTRACT
Objective To qualitatively and quantitatively investigate
thelinkbetweenalowestimatedglomerularfiltrationrate
(eGFR) at baseline and risk of future stroke.
Design Systematic review and meta-analysis of
prospective studies.
Data sources PubMed (1966-October 2009) and Embase
(1947-October 2009).
Selection criteria Inclusion criteria were studies that
prospectively collected data within cohort studies or
clinical trials, estimated glomerular filtration rate at
baseline usingthe modification of dietin renaldiseaseor
Cockcroft-Gault equations,assessedincidentstroke,had
a follow-upofatleastoneyear,andreportedquantitative
estimates of multivariate adjusted relative risk and 95%
confidence interval for stroke associated with an eGFR of
60-90 ml/min/1.73 m
2 or <60 ml/min/1.73 m
2.
Data abstraction Two investigators independently
abstracted data from eligible studies. Estimates were
combined using a random effects model. Heterogeneity
wasassessedbyPvalueofχ
2statisticsandI
2.Publication
bias was assessed by visual examination of funnel plots.
Results 21 articles derived from 33 prospective studies:
14articlesassessedeGFR<60ml/min/1.73m
2andseven
assessed eGRF at both <60 ml/min/1.73 m
2 and 60-
90 ml/min/1.73 m
2 for a total of 284672 participants
(follow-up3.2-15years)with7863strokeevents.Incident
stroke risk increased among participants with an eGFR
<60 ml/min/1.73 m
2 (relative risk 1.43, 95% confidence
interval 1.31 to 1.57; P<0.001) but not among those with
an eGFR of 60-90 ml/min/1.73 m
2 (1.07, 0.98 to 1.17;
P=0.15). Significant heterogeneity existed between
estimates among patients with an eGFR <60 ml/min/1.73
m
2 (P<0.001). In subgroup analyses among participants
with an eGFR <60 ml/min/1.73 m
2, heterogeneity was
significant in Asians compared with non-Asians (1.96,
1.73to2.23v1.25,1.16to1.35;P<0.001),andthosewith
an eGFR of 40-60 ml/min/1.73 m
2v <40 ml/min/1.73 m
2
(1.28, 1.04 to 1.56 v 1.77, 1.32 to 2.38; P<0.01).
Conclusions A baseline eGFR <60 ml/min/1.73 m
2 was
independently related to incident stroke across a variety
of participants and study designs. Prompt and
appropriate implementation of established strategies for
reduction of vascular risk in people with know renal
insufficiency may prevent future strokes.
INTRODUCTION
Chronickidneydiseaseandcardiovasculardiseaseare
major public health problems worldwide and often
share the same pathophysiological mechanisms.
1
Indeed, the prevalence of traditional cardiovascular
risk factors can be high in those with impaired kidney
function,
2andmostpatientswithanestimatedglomer-
ular filtration rate (eGFR) lower than 60 ml/min/1.73
m
2 die of cardiovascular causes and not progression to
end stage renal disease.
3 As such, averting future vas-
cular events in patients with a low eGFR should be a
primary goal.
4
Asystematicreviewofobservationalstudiesshowed
that a reduced eGFR was associated with an increased
risk of coronary heart disease,
5 and a recent meta-ana-
lysis showed that a low eGFR was linked to all cause
and cardiovascular mortality in the general
population.
6 The effect of reduced eGFR on incident
stroke,however,hasnotbeenwelldelineatedinaqua-
litativeorquantitativemannerusingthetotalityofpub-
lisheddata.Asstrokeisaleadingcauseofmortalityand
morbidity worldwide, and several strategies, such as
blood pressure control and use of statins and aspirin,
may reduce subsequent cardiovascular disease in
patients with chronic kidney disease, it is important to
identify people at potential high risk, then appropriate
therapy can be applied.
78We carried out a systematic
review and meta-analysis to determine whether a link
exists between reduced eGFR and incident stroke and
the magnitude of any relation.
METHODS
The search strategy was done according to the recom-
mendationsoftheMeta-analysisofObservational Stu-
dies in Epidemiology.
9 We searchedPubMed (1966 to
October 2009) and Embase (1947 to October 2009)
using the search strategy “glomerular filtration rate”
OR “renal disease” OR “chronic kidney disease”
AND “stroke” OR “cerebrovascular disease” OR
“cerebrovascular attack” OR “cerebral infarct” OR
“intracranial hemorrhage” AND “prospective” OR
1Stroke Center, 710 Westwood
Plaza, University of California, Los
Angeles, CA 90095, USA
2Department of Neurology,
University of California, Los
Angeles
3Department of Neurology, Chang
Gung Memorial Hospital at Chiayi,
Chang Gung University College of
Medicine, Taiwan
4Department of Neurology, Chang
Gung Memorial Hospital at Linkou,
Chang Gung University College of
Medicine
5Ching-Ten Clinic, Taiwan
6Department of Epidemiology,
School of Public Health, University
of California
Correspondence to: B Ovbiagele
Ovibes@mednet.ucla.edu
Cite this as: BMJ 2010;341:c4249
doi:10.1136/bmj.c4249
BMJ | ONLINE FIRST | bmj.com page 1 of 10“cohort” OR “observational” OR “post hoc” (see web
extra fig 1). We restricted the search to studies in
humans. No language restrictions were applied.
Further information was retrieved through a manual
search of references from recent reviews and relevant
published original studies.
Study selection and data abstraction
We included studies that prospectively collected data
within cohort studies or clinical trials, used the modifi-
cationofdietinrenaldiseaseorCockcroft-Gaultequa-
tions to estimate glomerular filtration rate at baseline,
assessedincidentstroke,hadafollow-upofatleastone
year, and reported quantitative estimates of the multi-
variateadjustedrelativeriskand95%confidenceinter-
val for stroke associated with an eGFR of 60-90 ml/
min/1.73 m
2 or <60 ml/min/1.73 m
2, or both. We
excluded studies that had a cross sectional, case-con-
trol,orretrospectivecohortstudy;thathadmostlypar-
ticipants with end stage renal disease (by history of
dialysis or an eGFR <15 ml/min/1.73 m
2) or kidney
transplant; that only reported unadjusted or age and
sex adjusted relative risk; that did not report 95% con-
fidenceintervals;andthatwereduplicated.Studiesthat
used slightly varying eGFR intervals were included if
they were otherwise comparable. Two investigators
(ML and K-HC) independently abstracted data from
eligiblestudies.Discrepancieswereresolvedbydiscus-
sion with a third investigator (BO) and by referencing
the original report.
Study quality
We assessed the quality of eligible studies. Assessment
was based on guidelines developed by the US Preven-
tiveTaskForceaswellasthemodifiedchecklistusedin
previousstudies.
10-12 We assessedeightcharacteristics:
prospective study design, maintenance of comparable
groups, adjustment of potential confounders, docu-
mented loss of follow-up rate, assessor of outcome
blinded to exposure status, clear definition of expo-
sures (eGFR) and outcomes (stroke), temporality
(eGFR measured at baseline, not at time of outcomes
assessment),and follow-upof at least oneyear. Studies
weregradedasgoodqualityiftheymetatleastsevenof
eight criteria, fair if they met four to six, and poor if
they met fewer than four.
Statistical analysis
For data analysis we used multivariate adjusted out-
come data (expressed as relative risks and 95% confi-
dence intervals). When articles provided estimates
based on both the modification of diet in renal disease
and the Cockcroft-Gault equations, we used estimates
from the more informative, expert recommended
modification of diet in renal disease equation
4 for pri-
maryanalysis.Ineachstudyweconvertedthesevalues
byusingtheirnaturallogarithms,andwecalculatedthe
standard errors from these logarithmic numbers and
their corresponding 95% confidence intervals. For the
statistical analysis we combined log relative risks and
standard errors using the inverse variance approach.
We used a random effect model and explored for
sources of inconsistency (I
2) and heterogeneity. A
fixed effect model was also used for comparison with
the random effects model on the overall risk estimate.
ReportedPvaluesweretwosided,withsignificanceset
at less than 0.05. Heterogeneity was assessed by P
valueofχ
2statisticsandI
2,whichdescribesthepercen-
tage of variability in the effect estimates that is due to
heterogeneity rather than to chance.
1314 Based on the
suggestionoftheCochraneCollaborationweregarded
heterogeneity as possibly unimportant when the I
2
value was less than 40% and considerable when more
than 75%.
15 RevMan 5 was used for the meta-analysis
of observational studies.
1617
The leading outcomes of interest were relative risks
of incident stroke in patients with an eGFR of 60-
90ml/min/1.73m
2and<60ml/min/1.73m
2.Publica-
tion bias was assessed by visual examination of funnel
plots. Subgroup analyses for eGFRs <60 ml/min/1.73
m
2 were done according to normal references (studies
using an eGFR >60 ml/min/1.73 m
2 as the normal
reference versus studies using >90 ml/min/1.73 m
2 as
normal), study population type (general or hyperten-
sion only versus established cardiovascular disease or
high cardiovascular risk at entry), study design (ordin-
arycohortsversussecondaryanalysisofclinicaltrials),
ethnicity (Asians v non-Asians), follow-up (<7 years v
≥7 years), number of participants (<10000 v ≥10000),
equationusedtodetermineeGFR(modificationofdiet
in renal disease v Cockcroft-Gault), end points (fatal v
fatal plusnon-fatal stroke),strokesubtype (ischaemicv
haemorrhagic stroke), sex (men v women), degree of
eGFR impairment (eGFR 40-60 ml/min/1.73 m
2 or
nearest equivalent v <40 ml/min/1.73 m
2 or nearest
equivalent), level of adjustment (age and sex adjusted
vmultivariateadjusted),andstudyquality(goodvfair).
We also explored the interaction between eGFR and
albuminuria by using as a reference those groups with
aneGFRof>60ml/min/1.73m
2withoutalbuminuria.
Overall search and review of abstracts (n=1754):
  PubMed (n=1504)
  Embase (n=250)
Full text articles retrieved for detailed assessment (n=83)
Articles included in meta-analysis (n=21):
  Estimated for eGFR <60 ml/min/1.73 m2 v reference only (n=14)
  Estimated for eGFR both 60-90 and <60 ml/min/1.73 m2
    v reference (n=7)
Excluded after review of abstract:
case-controlled, cross sectional, review,
duplication, no cardiovascular end point (n=1671)
Excluded (n=62):
  No multivariate adjusted stroke estimate (n=53)
  Duplicate studies (n=6)
  Retrospective cohort (n=3)
Fig 1 | Flow of study selection
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Study,
country
Study
population
Equation to
calculate
eGFR
eGFR
groups (ml/
min/1.73
m2)
No of
partici-
pants
%
men
Mean (SD) or
median
(range) age
(years)
No of
strokes
Follow-
up
(years) End points Adjusted variables
Study
quality
Bax 2008,
Nether-
lands
18
Atherosclero-
tic vascular
disease or
cardiovascular
risk factors at
entry
Modification
of diet in
renal
disease
>90
(reference);
60-90; <60
602; 2097;
517
83;77;
64
54 (10); 60
(10); 67 (8)
15; 59; 38 3.3 All stroke Age, sex, body mass index,
hypertension, coronary heart
disease, cerebral disease,
peripheral artery disease,
abdominal aortic aneurysm,
diabetes mellitus, smoking, and
use of angiotensin converting
enzyme inhibitors and
angiotensin II antagonists
Fair
Bos 2007,
Nether-
lands
19
General, no
stroke at entry
Cockcroft-
Gault
≥60
(reference);
<60
2652; 2285 40 69 (62 to 77) 586 10.2 All stroke
(ischaemic
and
haemorrha-
gic recorded
separately)
Age, sex, and propensity score
(systolicbloodpressure,diastolic
blood pressure, antihypertensive
drug use, left ventricular
hypertrophy, diuretic use, pack
years of smoking, diabetes
mellitus, cholesterol level, high
density lipoprotein level, carotid
intimamedia thickness, uricacid,
C reactive protein, previous
myocardial infarction, previous
atrialfibrillation,waisttohipratio,
antithrombotic drug use, lipid
lowering drug use)
Good
Cheng 2008,
Taiwan
20
General Modification
of diet in
renal
disease
>90
(reference);
60to90;<60
4190; 11
583; 1253
63;80;
87
56 (5); 57 (5);
61 (6)
29; 88; 35 15 Fatal stroke
(ischaemic
and
haemorrha-
gic recorded
separately)
Age, sex, body mass index,
smoking status (current, former,
never), total cholesterol level,
haemoglobin concentration,
diabetes mellitus, systolic blood
pressure, history of hypertension,
and prevalent cardiovascular
disease
Fair
Deo 2008,
USA
21
General, no
stroke at entry
Modification
of diet in
renal
disease
≥60
(reference);
<60
2340; 632 49 74 (70 to 79) 126; 37 6 All stroke Race, age, sex, site, body mass
index, alcohol use, current
smoking status, diabetes
mellitus, hypertension, aspirin
use, diuretic use, angiotensin
converting enzyme inhibitors use,
β blocker use, statin use, low
density lipoprotein and high
density lipoprotein cholesterol
level, plasminogen activator
inhibitor, C reactive protein,
albumin, interleukin-6, and
tumour necrosis factor α
Fair
Ford 2009,
Ireland,
Scotland, and
Nether-
lands
22
Pre-existing
vascular
disease or
increased risk
of such
disease,
secondary
analysis of
clinical trial
Modification
of diet in
renal
disease
≥60
(reference);
50-60; 40-
50; 20-40
2702; 1641;
1104; 349
58;48;
33; 26
75 (3); 75 (3);
76 (3); 77 (3)
190; 120;
74; 31
3.2 All stroke
and
transient
ischaemic
attacks
Randomised treatment; country;
sex; current smoking status; age;
histories of hypertension,
diabetes mellitus, and vascular
disease; levels of low density
lipoprotein cholesterol and high
density lipoprotein cholesterol;
systolic and diastolic blood
pressure; glucose level; body
massindex;andCreactiveprotein
Good
Go 2009,
USA
23
Atrial
fibrillation at
entry
Modification
of diet in
renal
disease
≥60
(reference);
45to59;<45
7690; 2499;
1338
60;48;
52
72 (64 to 78);
76 (70 to 82);
78 (73 to 83)
637 8 Thromboem-
bolic events,
94% were
ischaemic
stroke
Age, sex, race/ethnicity,
educational attainment, annual
income status, previous
ischaemic stroke, heart failure,
diabetes mellitus, hypertension,
and coronary artery disease
Good
Irie 2006,
Japan
24
General, men;
general,
women
Modification
of diet in
renal
disease
Men: ≥100
(reference),
60to99,<60.
Women:
≥100
(reference),
60to99, <60
Men: 7082,
23858,824.
Women: 10
554,48041,
2073
Men:
100 for
all
group-
s.
Wo-
men: 0
for all
groups
61 Men: 84,
363, 44.
Women:
53, 365,
76
10 Fatal stroke Age, hypertension category,
cigarettesmoking,alcoholintake,
diabetes mellitus, sex-specific
fifths of serum total cholesterol
level, serum high density
lipoproteincholesterollevel,body
mass index, and urinary protein
Fair
Kokubo2009,
Japan
25
General Modification
of diet in
≥90
(reference);
2415; 2452;
387; 124
47 56 65;99;36;
13
11.7 All stroke
(ischaemic
Age, sex, body mass index,
smoking, alcohol consumption,
Good
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country
Study
population
Equation to
calculate
eGFR
eGFR
groups (ml/
min/1.73
m2)
No of
partici-
pants
%
men
Mean (SD) or
median
(range) age
(years)
No of
strokes
Follow-
up
(years) End points Adjusted variables
Study
quality
renal
disease
60 to 89; 50
to 59; <50
and
haemorrha-
gic recorded
separately)
andpresentillness(hypertension,
diabetes mellitus, and
hypercholesterolaemia)
Koren- Morag
2006, Israel
26
Coronary heart
disease but
not stroke at
entry,
secondary
analysis of
clinical trial
Modification
of diet in
renal
disease and
Cockcroft-
Gault
>60
(reference);
≤60
5345; 1340 91; 79 58 (7); 65 (4) 207; 80 4.8to8.1 Ischaemic
stroke and
transient
ischaemic
attacks
Age, sex, systolic blood pressure,
diabetes mellitus, level of
triglycerides, high density
lipoprotein level, New York Heart
Associationfunctionalclass,body
mass index, peripheral artery
disease, current smoking status,
antiplatelets, antihypertensive
and lipid modifying drugs
Good
Kurth 2009,
USA
27
General,
female health
professionals,
no
cardiovascular
disease at
entry,
secondary
analysis of
clinical trial
Modification
of diet in
renal
disease
≥90
(reference);
75 to 89; 60
to 74; <60
14 979;
8073; 3572;
1315
0forall
groups
54 (0.1); 55
(0.1); 57 (0.1);
57 (0.2)
197; 111;
50; 31
12 All stroke Age, systolic blood pressure,
antihypertensive treatment,
smoking, body mass index,
alcohol,exercise,totalcholesterol
level, C reactive protein, use of
hormone replacement therapy,
diabetes mellitus, and assigned
treatments
Good
Nakayama
2007,Japan
28
General Cockcroft-
Gault
>70
(reference);
40to70;<40
555; 1246;
176
42;35;
35
55 (9); 65 (7);
76 (7)
15; 77; 20 7.8 All stroke Age, sex, systolic blood pressure,
bodymassindex,smokingstatus,
use of antihypertensive drugs,
history of cardiovascular disease,
hypercholesterolaemia, and
diabetes mellitus
Good
Nickolas
2008, USA
29
General, not
stroke at entry
Cockcroft-
Gault
≥60
(reference);
15 to 59
2353; 945 37 63 201 6.5 All stroke Age, sex, education,
hypertension, low density
lipoprotein cholesterol level,
diabetes mellitus, prevalent
cardiac disease, smoking, and
alcohol consumption
Good
Ninomiya
2008,Japan
30
General, data
from 10
community-
based cohort
studies
Modification
of diet in
renal
disease
≥90
(reference);
60to89;<60
7206; 14
003; 1875
39;56;
5
58 (12) 84; 404;
104
7.4 All stroke Age, sex, cohort, systolic blood
pressure, diabetes mellitus, total
cholesterol level, body mass
index,andcurrentsmokingstatus
Fair
Perkovic
2007,
multicoun-
tries
38
Stroke,
secondary
analysis of
clinical trial
Cockcroft-
Gault
≥60
(reference);
<60
4314; 1757 75; 55 61 (9); 70 (8) 460; 264 4 All stroke Age, sex, smoking status,
diabetes mellitus, systolic blood
pressure,bodymassindex,active
versus placebo therapy, and
single versus dual agent therapy
Good
Perticone
2009, Italy
31
Postmenopau-
sal women, no
cardiovascular
disease or
diabetes
mellitus at
entry
Modification
of diet in
renal
disease
≥60
(reference);
<60
1071; 429 0; 0 53 (6); 53 (6) 41; 24 6 All stroke Age, smoking (former or never
smokers, current smokers),
cholesterol level, systolic blood
pressure, fasting glucose level,
body mass index, menopause,
and metabolic syndrome
Fair
Ruilope2001,
Multicoun-
tries
32
Hypertension
cohort,
secondary
analysis of
clinical trial
Cockcroft-
Gault
>60
(eference);
≤60
15 770;
2821
57; 30 60 (7); 68 (7) 211; 77 3.8 All stroke Achieved diastolic and systolic
blood pressure, age, gender,
smoking habits, previous
cardiovascular disease, diabetes
mellitus, and total cholesterol
Good
Ruilope2007,
multicoun-
tries
33
Hypertension
cohort,
secondary
analysis of
clinical trial
Modification
of diet in
renal
disease and
Cockcroft-
Gault
≥60
(reference);
<60
9214; 5999 67; 44 65 (8); 70 (8) 603 4.6 All stroke Age, sex, coronary heart disease,
and left ventricular hypertrophy
Good
Shilipak
2001, USA
34
Postmenopau-
sal women
with coronary
heart disease,
secondary
analysis of
clinical trial
Cockcroft-
Gault
>60
(reference);
40to60;<40
1306; 1135;
322
0forall
groups
66 (7) 70; 93; 51 4.1 All stroke
and
transient
ischaemic
attacks
Age;race; hypertension;diabetes
mellitus; tobacco use; previous
coronary artery bypass surgery;
body mass index; waist to hip
ratio; levels of low density
lipoprotein cholesterol, high
density lipoprotein cholesterol,
triglyceride, and lipoprotein(a);
physical activity; lipid lowering
Good
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The literature review identified 83 full articles for
detailed assessment, of which 53 were excluded for
having no multivariate adjusted stroke estimate, six
forbeingduplicatedstudies,andthreeforhavingaret-
rospective cohort design. Our final primary analysis
included 21 articles derived from 33 prospective
studies
18-38: 14 articles assessed eGFR <60 ml/min/
1.73 m
2 only and seven assessed both <60 ml/min/
1.73 m
2 and 60-90 ml/min/1.73 m
2 (fig 1). The table
showsthecharacteristicsoftheincludedstudies.Over-
all, 284672 participants had a total of 7863 stroke
events. Among the 21 articles, one contained 10 com-
munity cohorts from Japan
30 and the other four com-
munity cohorts from the United States.
36 Participants
were derived from ordinary cohorts in 13 articles and
clinicaltrialsineight.Onascaleof8theoverallquality
of studies was good (median score 7, range 5-8).
Follow-uprangedfrom3.2
22to15years.
20Glomerular
filtrationratewasestimatedbythemodificationofdiet
inrenaldiseaseequationin15articlesandbytheCock-
croft-Gault equation in six. Nineteen articles reported
fatal plus non-fatal stroke as a primary end point,
whereas two reported fatal stroke as a primary end
point.
2024 One study used thromboembolic events as
a primary end point, but ischaemic stroke constituted
over 94% of total thromboembolic events.
23 Transient
ischaemic attacks were only included as end points in
three studies.
222634
Main outcome
Poolingresultsfromtherandomeffectsmodelshowed
that incident stroke increased among patients with an
eGFR <60 ml/min/1.73 m
2 (relative risk 1.43, 95%
confidence interval 1.31 to 1.57, P<0.001; fig 2). The
risk of incident stroke did not, however, increase
Study,
country
Study
population
Equation to
calculate
eGFR
eGFR
groups (ml/
min/1.73
m2)
No of
partici-
pants
%
men
Mean (SD) or
median
(range) age
(years)
No of
strokes
Follow-
up
(years) End points Adjusted variables
Study
quality
drug use; diuretic use; and atrial
fibrillation
Tonelli 2006,
USA and
Canada
35
History of
myocardial
infarction,
secondary
analysis of
clinical trial
Modification
of diet in
renal
disease
≥60
(reference);
<60
2839; 707 89; 75 58 (50 to 64);
65 (59 to 70)
71; 28 5 All stroke Age, sex, ethnic origin, smoking
status,diabetesmellitus,waistto
hip circumference ratio, fasting
glucose level, haemoglobin
concentration, albumin, low
density lipoprotein and high
density lipoprotein cholesterol
levels, triglyceride levels, systolic
and diastolic blood pressure,
country of treatment (US v
Canada), left ventricular ejection
fraction, and use of drugs (β
blockers, angiotensin converting
enzyme inhibitors, aspirin, or
pravastatin)
Good
Weiner 2004,
USA
36
Combined four
population
studies
(Atherosclero-
sis Risk in
Community
Study,
Cardiovascular
Health Study,
Framingham
Heart Study,
and
Framingham
Offspring
Study)
Modification
of diet in
renal
disease
≥60
(reference);
15 to 59
20 970;
1664
44; 33 56 (11); 68
(11)
587; 125 10 All stroke Age, sex, hypertension, diabetes
mellitus, systolic blood pressure,
body mass index, total and high
density lipoprotein cholesterol
level, current smoking status,
current alcohol use, left
ventricular hypertrophy, high
school graduation status, and
race
Fair
Yang 2008,
China
37
Diabetic
population
without stroke
at entry
Modification
of diet in
renal
disease
≥115
(reference);
60 to 114.9;
<60
6969 46 57 314 5.4 Ischaemic
stroke
Age; sex; systolic and diastolic
bloodpressure;haemoglobinA1c;
body mass index; haemoglobin
concentration; white blood cell
count; levels of high density
lipoprotein, low density
lipoprotein, total cholesterol, and
triglyceride; and drug use (blood
pressure lowering, cholesterol
lowering, insulin, antiplatelet,
angiotensin converting enzyme
inhibitor, and angiotensin II
antagonist)
Fair
eGFR=estimated glomerular filtration rate.
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90 ml/min/1.73 m
2 (1.07, 0.98 to 1.17, P=0.15; fig 2).
Significant heterogeneity existed between estimates
among patients with an eGFR <60 ml/min/1.73 m
2
(P<0.001, I
2=69%) but not among those with an
eGFR of 60-90 ml/min/1.73 m
2 (P=0.06, I
2=38%).
The estimates were similar between the fixed effects
model and random effect model.
Subgroup analyses
An eGFR <60 ml/min/1.73 m
2 was associated with an
increased risk of subsequent stroke in all subgroups
when estimates were stratified by eGFR reference
group, study population type, study design, ethnicity,
duration of follow-up, number of participants, equa-
tion used to determine eGFR, end points, sex, stroke
subtype, different eGFR intervals <60 ml/min/1.73
m
2, study quality, and level of adjustment (fig 3). Sig-
nificant heterogeneity between pooled analyses were
noted for studies using an eGFR >60 ml/min/1.73 m
2
as the normal reference compared with studies using
>90 ml/min/1.73 m
2 as normal (1.29, 1.18 to 1.41 v
1.82, 1.53 to 2.16, P for heterogeneity among sub-
groups <0.001), cohort studies compared with clinical
trials (1.59, 1.40 to 1.81 v 1.25, 1.13 to 1.38, P<0.01),
Asianscomparedwithnon-Asians(1.96,1.73to2.23v1.26,
1.16 to 1.35, P<0.001), fatal compared with fatal plus
non-fatal stroke (1.97, 1.63 to 2.38 v 1.38, 1.26 to 1.51,
P<0.001), eGFR 40-60 ml/min/1.73 m
2v <40 ml/min/
1.73 m
2 (1.28, 1.04 to 1.56 v 1.77, 1.32 to 2.38, P<0.01),
a n dg o o ds t u d yq u a l i t yc o m p a r e dw i t hf a i rs t u d yq u a l i t y
(1.35, 1.23 to 1.49 v1.62, 1.33 to 1.97, P=0.01).
A total of 11 studies reported adjusted estimates of
thestrengthoftheassociation,firstbyageandsexthen
byotherknowncardiovascularriskfactors—forexam-
ple, blood pressure, smoking, lipids levels, diabetes.
The overall age and sex adjusted summary estimate
was 1.64 (95% confidence interval 1.45 to 1.85),
which after further adjustment of other known cardio-
vascular risk factors was reduced to 1.45 (1.26 to 1.68;
P for heterogeneity among subgroups 0.01).
Otherwiseno obvious heterogeneity found between
baseline risk populations (general or hypertension
only v high cardiovascular risk), duration of follow-
up,numberofparticipants,equationusedtodetermine
eGFR, stroke subtypes, and sex. Based on the few
papers that provided information on the interaction
between proteinuria and eGFR, proteinuria did not
substantially increase the risk of stroke in patients
with an eGFR of <60 or >60 ml/min/1.73 m
2 (fig 4).
Publication bias
The funnel plots showed no major asymmetry except
for a small degree of publication bias, with a slight
under-representation of small studies showing neutral
or unexpected protective effects (see web extra fig 2).
DISCUSSION
Inthismeta-analysisof21articlesderivedfrom33pro-
spectivestudiesof generallygood quality, amongover
280000 people experiencing almost 8000 stroke
events,wefoundthatpatientswithabaselineestimated
glomerular filtration rate (eGFR) of <60 ml/min/1.73
m
2hadariskoffuturestrokethatwas43%greaterthan
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Fig 2 | Risk ratio for association of estimated glomerular filtration rate (eGFR) and risk of stroke
in prospective cohort studies. *Subgroups of estimates with eGFR <60 ml/min/1.73 m
2.
†Subgroups of estimates with eGFR 60-90 ml/min/1.73 m
2
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page 6 of 10 BMJ | ONLINE FIRST | bmj.comthose with a normal baseline eGFR. This relation was
consistent across diverse population subgroups—that
is, those with or without traditional cardiovascular
risk factors. The size and inclusion of only prospec-
tively collected data strengthened the robustness of
our findings, as selection bias, recall bias, and reverse
causality were unlikely. In addition, all studies
included in our meta-analysis reported a multivariate
adjusted relative risk, which probably mitigated the
possibility of known confounding influencing our
results.
We used subgroup analyses to assess the varying
influence of several factors on the association between
eGFR <60 ml/min/1.73 m
2 and risk of stroke. The
magnitude of risk was larger when studies used an
eGFR >90 ml/min/1.73 m
2 as reference compared
with >60 ml/min/1.73 m
2, which raised the possibility
that an eGFR of 60-90 ml/min/1.73 m
2 may increase
t h er i s ko fs t r o k ec o m p a r e dw i t ha ne G F R> 9 0m l /
min/1.73 m
2. Our formal meta-analysis did not, how-
ever, show significantly increased risk of incident stroke
among patients with an eGFR of 60-90 ml/min/1.73 m
2.
The explanation could be that such a rate is not sensitive
enoughasamarkerofkidneydiseasetodiscriminaterisk
ofstroke.Wedid,however,findapossibledose-response
relationbetweeneGFRandstrokeatlevels<60ml/min/
1.73 m
2—that is, the risk of stroke was significantly
greater for eGFR <40 ml/min/1.73 m
2 than for levels
of 40-60 ml/min/1.73 m
2.
A meta-analysis based on observational studies can-
not prove causality. However, based on these results it
may not be unreasonable to regard the presence of a
low eGFR as a marker for increased risk of stroke,
prompting optimal application of established vascular
risk reduction strategies such as control of blood pres-
sure, statin use, and antiplatelet therapy.
7
Interestingly we found that Asian people with a low
baseline eGFR seemed to be at higher risk of future
stroke. Indeed, in Asian populations, hypertension is
a major risk factor of both stroke and death from renal
causes,
3940chronickidneydiseasefurtherincreasesthe
association of blood pressure with stroke,
25 and meta-
analysis showed that the risk of stroke associated with
hypertensionisconsistentlyandsignificantlygreaterin
Chinese than in white people.
41 Furthermore, it has
been suggested that Asian people tend to develop
hypertension at earlier ages than other races,
42 and it
is conceivable that a longer history of hypertension
may cause more profound damage of end organs and
vesselstherebyleadingtoa higherlikelihoodofvascu-
lar events within a given study period. A systematic
review that linked reduced eGFR with increased risk
of coronary heart disease was only among participants
in Western countries and so did not have the means of
exploring this issue.
5 Although most of the studies we
analysed adjusted for hypertension or blood pressure,
none adjusted for the duration of hypertension,
thereby limiting the extent to which we could fully
adjust for hypertension as a confounder. As such, this
potential disparity between races will need to be more
comprehensively explored in future studies.
We also observed that the effect of reduced eGFR
was more profound on the risk of fatal stroke than on
all strokes, which probably points to the association of
compromisedkidneyfunctionwithriskfactorsforgen-
erally poor clinical outcomes such as oxidative stress,
widespread inflammation, electrolyte derangements,
procoagulation, and presence of uraemic toxins.
3 In
fact, kidney disease even of mild severity has been
shown to be an independent predictor of poorer clin-
ical outcomes among people with stroke, including
higher risk of all cause mortality and cardiovascular
mortality.
4344Alsoofnote,thepresenceofalbuminuria
did not substantially further increase the risk of stroke
among patients with a baseline eGFR of <60 or
References of eGFR (ml/min/1.73 m
2)
  eGFR >60 
  eGFR >90 
Study population
  General or hypertension only
  High risk of cardiovascular disease
Study design
  Ordinary cohorts
  Analysis of trials
Ethnicity
  Asians
  Non-Asians
Follow-up duration
  <7 years
 ≥7 years
No of participants
  <10 000
 ≥10 000
Equation
  Modification of diet in renal disease
  Cockcroft-Gault
End points
  Fatal stroke
  Fatal and non-fatal stroke
Stroke subtypes
  Ischaemic
  Haemorrhagic
Sex
  Men
  Women
Degree of renal insufficiency
  eGFR 40-60 ml/min/1.73 m2
  eGFR <40 ml/min/1.73 m2
Study quality
  Good
  Fair
Level of adjustment
  Age and sex
  Multivariate
1.29 (1.18 to 1.41)
1.82 (1.53 to 2.16)
1.58 (1.36 to 1.84) 
1.34 (1.20 to 1.50)
1.59 (1.40 to 1.81)
1.25 (1.13 to 1.38)
1.96 (1.73 to 2.23)
1.26 (1.16 to 1.35)
1.35 (1.20 to 1.52)
1.55 (1.34 to 1.80)
1.47 (1.29 to 1.67)
1.39 (1.22 to 1.59)
1.41 (1.26 to 1.58)
1.44 (1.26 to 1.66)
1.97 (1.63 to 2.38)
1.38 (1.26 to 1.51)
1.98 (1.47 to 2.66)
1.87 (0.98 to 3.59)
1.74 (1.28 to 2.35)
1.62 (1.36 to 1.93)
1.28 (1.04 to 1.56)
1.77 (1.32 to 2.38)
1.35 (1.23 to 1.49)
1.62 (1.33 to 1.97)
1.64 (1.45 to 1.85)
1.45 (1.26 to 1.68)
14
7
10
11
13
8
6
14
12
9
13
8
15
8
2
19
6
3
3
6
5
5
13
8
11
11
0.1 1 10
Subgroups
Protective
against stroke
Excess risk
of stroke
Risk ratio
(95% CI)
Risk ratio
(95% CI)
<0.001
0.12
<0.01
<0.001
0.11
0.61
0.80
<0.001
0.10
0.36
<0.01
0.01
0.01
P value for
heterogeneity
No of
studies
Fig 3 | Subgroup analyses for comparison between studies reporting associations of estimated
glomerular filtration rate (eGFR) <60 ml/min/1.73 m
2 with risk of stroke
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2.Ourresultshouldbeinterpreted
with caution, however, as it was based on just three
studies and the rate of albuminuria is low in people
without diabetes. A recent meta-analysis showed that
compared with people without albuminuria or a low
eGFR, those with either condition had a higher risk
ofcardiovasculardeathandthosewithbothconditions
had the highest risk of cardiovascular death.
6 Further-
more,meta-analyseshaveshownthatalbuminuriawas
independently associated with a higher risk of stroke
evenwhentheincludedstudieshadadjustedforeGFR
or serum creatinine level.
4546
Limitations of this meta-analysis
Limitations of this meta-analysis must be considered.
Firstly, meta-analyses may be biased if the literature
search fails to identify all relevant studies or the selec-
tion criteria for including a study are applied in a sub-
jectivemanner.Tominimisetheseriskswe carriedout
thorough searches across different databases using
explicit criteria for study selection, data abstraction,
and data analysis. Secondly, compared with studies of
good quality, those of fair quality showed a stronger
association between reduced eGFR and stroke. When
we restricted analysis to good quality studies, the esti-
mate of association slightly decreased. Thirdly, a large
amountofheterogeneity wasobservedinthe resultsof
the various studies. Although subanalyses were done
to identify this, heterogeneity persisted in many sub-
groups, suggesting that other factors might explain
this result. Meta-regression by average baseline
eGFR and other variables could have been a better
way of exploring potential sources of heterogeneity.
However, most included articles did not provide aver-
age baseline eGFR in each eGFR category, which pre-
vented us from exploring further. In those studies that
provided both age and sex adjusted and multivariate
unadjustedestimates,theassociationbetweenreduced
eGFRandstrokewasslightly,butsignificantly,attenu-
ated after further adjustment. Such an attenuation in
effect size suggests that residual confounding may
have remained and that the summary result presented
here may be a slight overestimation of the true magni-
tudeoftheassociationbetweenreducedeGFRandrisk
of stroke. Despite these limitations, the results of this
systematicreviewrepresentthemostpreciseandaccu-
rate estimate of the strength of the relation between
reducedeGFRandincidentstrokecurrentlyavailable.
Implications
Our formal meta-analysis found a significant associa-
tion between eGFR <60 ml/min/1.73 m
2 and
increased incident stroke across various populations,
afteradjustmentforestablishedcardiovascularriskfac-
tors. None the less, these results possibly underesti-
mated the magnitude of this relation because a
reducedeGFRoftensimultaneouslyexistswithseveral
traditional and novel vascular risk factors. Of major
public health interest were our findings that Asian
patientswith a low eGFRwere at higher risk for stroke
thantheirnon-Asiancounterparts,thatbelowaneGFR
level of 60 ml/min/1.73 m
2 a dose-response relation
with risk of stroke might exist, and that fatal strokes
were especially associated with low baseline eGFR.
Atthisjuncture,alowbaselineeGFRshouldbeseen
simply as a risk marker. Established evidence based
strategies already proved to mitigate vascular risk,
such as reduction of blood pressure, when promptly
and appropriately applied are likely to avert future
strokes in people with renal insufficiency. Specific
patient subgroups with a low eGFR, such as people of
Asian race, may particularly benefit.
We thank Yueh Lee for retrieving the papers.
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Fig 4 | Interaction between estimated glomerular filtration rate (eGFR) and albuminuria, using
groups with eGFR >60 ml/min/1.73 m
2 without albuminuria as reference
WHAT IS ALREADY KNOWN ON THIS TOPIC
Most patients with an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m
2 die of
cardiovascular causes and not progression to end stage renal disease
A recent meta-analysis showed that an eGFR <60 ml/min/1.73 m
2 was associated with all
cause and cardiovascular mortality in the general population
WHAT THIS STUDY ADDS
People with a baseline eGFR <60 ml/min/1.73 m
2 had an independent risk of future stroke
that was 43% greater than those with a normal baseline eGFR
Adose-responserelationbetweeneGFR<60ml/min/1.73m
2andriskofstrokewasobserved,
with risk of stroke being significantly greater for levels <40 ml/min/1.73 m
2 compared with
40-60 ml/min/1.73 m
2
Asian patients with an eGFR <60 ml/min/1.73 m
2 w e r ea th i g h e rr i s ko fs t r o k et h a np e o p l eo f
non-Asian ethnicity
RESEARCH
page 8 of 10 BMJ | ONLINE FIRST | bmj.comContributors: ML and BO conceived the study. ML, S-CC, and BO design
the inclusion and exclusion criteria. ML, and K-HC participated in the
study search and data collection and extraction. ML did the statistical
analysis with guidance from JLS, S-CC, and BO. ML wrote the first draft of
the report, and JLS, H-WL, and BO did the major revision and made
comments. All other authors commented on the draft and approved the
final version. ML and BO had full access to all the data and had the final
decision to submit for publication. They are guarantors.
Funding: ML was supported by a grant from Chang Gung Memorial
Hospital, Taiwan (CMRPG 660311, Taiwan). JLS was supported by the
specialised programme on translational research in acute stroke
(SPOTRIAS) award (P50 NS044378) from the National Institutes of
Health, and BO was supported by University of California, Los Angeles-
ResourceCentersforMinorityAgingResearchunderNationalInstitutesof
Health/National Institutes on Aging grant No P30-AG021684. The
sponsors played no role in the study design, data collection and analysis,
or decision to submit the article for publication.
Competing interests: All authors have completed the Unified Competing
Interest form at www.icmje.org/coi_disclosure.pdf (available on request
from the corresponding author) and declare: no support from any
company for the submitted work; no financial relationships with any
companies that might have an interest in the submitted work in the
previous 3 years; no other relationships or activities that could appear to
have influenced the submitted work.
Ethical approval: Not required.
Data sharing: No additional data available.
1 R o s a m o n dW ,F l e g a lK ,F r i d a yG ,F u r i eK ,G oA ,G r e e n l u n dK ,e ta l .
Heart disease and stroke statistics—2007 update: a report from the
American Heart Association Statistics Committee and Stroke
Statistics Subcommittee. Circulation 2007;115:e69-171.
2 SarnakMJ,LeveyAS,SchoolwerthAC,CoreshJ,CulletonB,HammLL,
et al. Kidney disease as a risk factor for development of
cardiovascular disease: a statement from the American Heart
Association Councils on Kidney in Cardiovascular Disease, High
Blood Pressure Research, Clinical Cardiology, and Epidemiology and
Prevention. Circulation 2003;108:2154-69.
3 Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on
the cardiovascular system. Circulation 2007;116:85-97.
4 Brosius FC, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM,
MooreMA,etal.Detectionofchronickidneydisease inpatientswith
or at increased risk of cardiovascular disease: a science advisory
from the American Heart Association Kidney and Cardiovascular
Disease Council; the Councils on High Blood Pressure Research,
Cardiovascular Disease in the Young, and Epidemiology and
Prevention; and the Quality of Care and Outcomes Research
Interdisciplinary Working Group: developed in collaboration with the
National Kidney Foundation. Circulation 2006;114:1083-7.
5 Di Angelantonio E, Danesh J, Eiriksdottir G, Gudnason V. Renal
function and risk of coronary heart disease in general populations:
new prospective study and systematic review. PLoS Med
2007;4:e270.
6 Association of estimated glomerular filtration rate and albuminuria
with all-cause and cardiovascular mortality in general population
cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81.
7 James MT, Hemmelgarn BR, Tonelli M. Early recognition and
prevention of chronic kidney disease. Lancet 2010;375:1296-309.
8 Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F,
Nicolucci A, et al. Effects of statins in patients with chronic kidney
disease: meta-analysis and meta-regression of randomised
controlled trials. BMJ 2008;336:645-51.
9 S t r o u pD F ,B e r l i nJ A ,M o r t o nS C ,O l k i nI ,W i l l i a m s o nG D ,R e n n i eD ,
et al. Meta-analysis of observational studies in epidemiology: a
proposal for reporting. Meta-analysis Of Observational Studies in
Epidemiology (MOOSE) group. JAMA 2000;283:2008-12.
10 Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM,
et al. Current methods of the US Preventive Services Task Force: a
review of the process. A mJP r e vM e d2001;20:21-35.
11 Loosemore M, Knowles CH, Whyte GP. Amateur boxing and risk of
chronic traumatic brain injury: systematic review of observational
studies. BMJ 2007;335:809.
12 Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO,
D i C a p u aP ,e ta l .R e n a li m p a i r m e n ta n do u t c o m e si nh e a r tf a i l u r e :
systematic review and meta-analysis. JA mC o l lC a r d i o l
2006;47:1987-96.
13 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. BMJ 2003;327:557-60.
14 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-
analysis. Stat Med 2002;21:1539-58.
15 Higgins JPT, Green S. Cochrane handbook for systematic reviews of
interventions. Cochrane Collaboration, 2008.
16 Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent
venous thromboembolism in patients with common thrombophilia:
as y s t e m a t i cr e v i e w .Arch Intern Med 2006;166:729-36.
17 Critchley JA, Capewell S. Mortality risk reduction associated with
smoking cessation in patients with coronary heart disease: a
systematic review. JAMA 2003;290:86-97.
18 B a xL ,A l g r aA ,M a l iW P ,E d l i n g e rM ,B e u t l e rJ J ,v a nd e rG r a a fY .R e n a l
functionasariskindicatorforcardiovasculareventsin3216patients
with manifest arterial disease. Atherosclerosis 2008;200:184-90.
19 Bos MJ, Koudstaal PJ, Hofman A, Breteler MM. Decreased glomerular
filtration rate is a risk factor for hemorrhagic but not for ischemic
stroke: the Rotterdam Study. Stroke 2007;38:3127-32.
20 Cheng TY, Wen SF, Astor BC, Tao XG, Samet JM, Wen CP. Mortality
risksforallcausesandcardiovasculardiseasesandreducedGFRina
middle-aged working population in Taiwan. A mJK i d n e yD i s
2008;52:1051-60.
2 1 D e oR ,F y rC L ,F r i e dL F ,N e w m a nA B ,H a r r i sT B ,A n g l e m a nS ,e ta l .
Kidney dysfunction and fatal cardiovascular disease—an
association independent of atherosclerotic events: results from the
H e a l t h ,A g i n g ,a n dB o dyC o m p o s i t i o n( H e a l t hA B C )s t u d y .Am Heart J
2008;155:62-8.
22 Ford I,BezlyakV,Stott DJ,SattarN,PackardCJ,PerryI,etal. Reduced
glomerular filtration rate and its association with clinical outcome in
older patients at risk of vascular events: secondary analysis. PLoS
Med 2009;6:e16.
23 Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L,
et al. Impact of proteinuria and glomerular filtration rate on risk of
thromboembolism in atrial fibrillation: the anticoagulation and risk
factors in atrial fibrillation (ATRIA) study. Circulation
2009;119:1363-9.
24 Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, et al.
The relationships of proteinuria, serum creatinine, glomerular
filtration rate with cardiovascular disease mortality in Japanese
general population. Kidney Int 2006;69:1264-71.
25 Kokubo Y, Nakamura S, Okamura T, Yoshimasa Y, Makino H,
Watanabe M, et al. Relationship between blood pressure category
and incidence of stroke and myocardial infarction in an urban
Japanese population with and without chronic kidney disease: the
Suita Study. Stroke 2009;40:2674-9.
26 Koren-Morag N, Goldbourt U, Tanne D. Renal dysfunction and risk of
ischemic stroke or TIA in patients with cardiovascular disease.
Neurology 2006;67:224-8.
27 Kurth T, de Jong PE, Cook NR, Buring JE, Ridker PM. Kidney function
and risk of cardiovascular disease and mortality in women: a
prospective cohort study. BMJ 2009;338:b2392.
28 Nakayama M, Metoki H, Terawaki H, Ohkubo T, Kikuya M, Sato T,
et al. Kidney dysfunction as a risk factor for first symptomatic stroke
events in a general Japanese population—the Ohasama study.
N e p h r o lD i a lT r a n s p l a n t2007;22:1910-5.
29 Nickolas TL, Khatri M, Boden-Albala B, Kiryluk K, Luo X,
Gervasi-Franklin P, et al. The association between kidney disease
and cardiovascular risk in a multiethnic cohort: findings from the
Northern Manhattan Study (NOMAS). Stroke 2008;39:2876-9.
30 Ninomiya T, Kiyohara Y, Tokuda Y, Doi Y, Arima H, Harada A, et al.
Impact of kidney disease and blood pressure on the development of
cardiovascular disease: an overview from the Japan Arteriosclerosis
Longitudinal Study. Circulation 2008;118:2694-701.
3 1 P e r t i c o n eF ,S c i a c q u aA ,M a i oR ,P e r t i c o n eM ,L a i n oI ,B r u n iR ,e ta l .
Renal function predicts cardiovascular outcomes in southern Italian
postmenopausal women. Eur J Cardiovasc Prev Rehabil
2009;16:481-6.
32 Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H,
et al. Renal function and intensive lowering of blood pressure in
hypertensive participants of the hypertension optimal treatment
(HOT) study. JA mS o cN e p h r o l2001;12:218-25.
33 Ruilope LM, Zanchetti A, Julius S, McInnes GT, Segura J, Stolt P, et al.
Prediction of cardiovascular outcome by estimated glomerular
filtration rate and estimated creatinine clearance in the high-risk
hypertension population of the VALUE trial. JH y p e r t e n s
2007;25:1473-9.
3 4 S h l i p a kM G ,S i m o nJ A ,G r a d yD ,L i nF ,W e n g e rN K ,F u r b e r gC D .R e n a l
insufficiency and cardiovascular events in postmenopausal women
with coronary heart disease. JA mC o l lC a r d i o l2001;38:705-11.
35 Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M.
Proteinuria, impaired kidney function, and adverse outcomes in
people with coronary disease: analysis of a previously conducted
randomised trial. BMJ 2006;332:1426.
36 Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL,
et al. Chronic kidney disease as a risk factor for cardiovascular
disease and all-cause mortality: a pooled analysis of community-
based studies. J Am Soc Nephrol 2004;15:1307-15.
37 YangX,SoWY,MaRC,KoGT,KongAP,HoCS,etal.Thresholdsofrisk
factors for ischemic stroke in type 2 diabetic patients with and
without albuminuria: a non-linear approach. Clin Neurol Neurosurg
2008;110:701-9.
38 PerkovicV,NinomiyaT,ArimaH,GallagherM,JardineM,CassA,etal.
Chronic kidney disease, cardiovascular events, and the effects of
perindopril-basedbloodpressurelowering:datafromthePROGRESS
study. J Am Soc Nephrol 2007;18:2766-72.
3 9 N a k a m u r aK ,B a r z iF ,L a mT H ,H u x l e yR ,F e i g i nV L ,U e s h i m aH ,e ta l .
Cigarette smoking, systolic blood pressure, and cardiovascular
diseases in the Asia-Pacific region. Stroke 2008;39:1694-702.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 9 of 1040 O ’ S e a g h d h aC M ,P e r k o v i cV ,L a mT H ,M c G i n nS ,B a r z iF ,G uD F ,e ta l .
Blood pressure is a major risk factor for renal death: an analysis of
560 352 participants from the Asia-Pacific region. Hypertension
2009;54:509-15.
41 Zhang XF, Attia J, D’Este C, Ma XY. The relationship between higher
blood pressure and ischaemic, haemorrhagic stroke among Chinese
and Caucasians: meta-analysis. Eur J Cardiovasc Prev Rehabil
2006;13:429-37.
42 Hohn AR, Dwyer KM, Dwyer JH. Blood pressure in youth from four
ethnic groups: the Pasadena Prevention Project. JP e d i a t r
1994;125:368-73.
43 Ovbiagele B, Sanossian N, Liebeskind DS, Kim D, Ali LK, Pineda S,
et al. Indices of kidney dysfunction and discharge outcomes in
hospitalized stroke patients without known renal disease.
Cerebrovasc Dis 2009;28:582-8.
44 Ani C, Ovbiagele B. Relation of baseline presence and severity of
renal disease to long-term mortality in persons with known stroke. J
Neurol Sci 2010;288:123-8.
45 Ninomiya T, Perkovic V, Verdon C, Barzi F, Cass A, Gallagher M, et al.
Proteinuria and stroke: a meta-analysis of cohort studies. Am J
Kidney Dis 2009;53:417-25.
46 LeeM,SaverJL,ChangKC,OvbiageleB.Levelofalbuminuriaandrisk
of stroke: systematic review and meta-analysis. Cerebrovasc Dis
2010 (in press).
Accepted: 25 June 2010
RESEARCH
page 10 of 10 BMJ | ONLINE FIRST | bmj.com